Three dozen institutional investors are urging the boards at several of the world’s largest pharmaceutical companies to establish concrete metrics for linking executive compensation with policies that widen access to medicines to low- and middle-income countries.
In a series of letters, the investors asked the heads of board compensation committees to examine such steps as voluntary licensing agreements and technology transfer for generic production; supply chain performance for improving access to poor countries; transparency surrounding pricing policies; and access plans that focus specifically on diseases that affect people in these countries.
The letters were sent to Pfizer, AbbVie, Novartis, Eli Lilly, Gilead Sciences, Aspen Pharmacare, Johnson & Johnson, Moderna, Merck, Biogen, and AstraZeneca.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect